Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from CSL ( (AU:CSL) ).
CSL Limited has announced the cessation of Megan Clark as a director, effective October 28, 2025. This change in the board composition is accompanied by details of her interests in the company’s securities, which include 3,883 ordinary fully paid shares held directly and additional shares and rights held indirectly through Solium Nominees (Australia) Pty Ltd. This update is part of CSL’s compliance with regulatory requirements and may influence stakeholders’ perspectives on the company’s governance and strategic direction.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$275.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited operates in the biopharmaceutical industry, focusing on the development and delivery of innovative medicines and vaccines. The company is known for its contributions to global health through its extensive range of products and services, catering to various healthcare needs worldwide.
Average Trading Volume: 1,206,320
Technical Sentiment Signal: Sell
Current Market Cap: A$103.1B
Learn more about CSL stock on TipRanks’ Stock Analysis page.